Fortrea launches as leading, global contract research organization positioned to bring life-changing therapies to patients faster

Company completes spin-off from labcorp and begins trading on nasdaq under ticker “ftre” independent company positioned to capitalize on growth opportunities in phases i-iv clinical trials and patient access, and to extend leading positions in oncology, clinical pharmacology and partnership models durham, n.c., july 03, 2023 (globe newswire) -- fortrea (nasdaq: ftre) (the “company”), a leading global contract research organization (cro), today announced that it has successfully completed its previously announced spin-off from labcorp (nyse: lh).
LH Ratings Summary
LH Quant Ranking